Drug Database
CE

celecoxib + tramadol HCl (MR308 / Velyntra / Seglentis)

✓ Approved

Kowa · OPRM1 · Small Molecule

What is celecoxib + tramadol HCl?

celecoxib + tramadol HCl is a small molecule developed by Kowa. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesMR308, Velyntra, Seglentis
CompanyKowa
Drug ClassSmall Molecule
Molecular TargetOPRM1, PTGS2, SLC6A2, SLC6A4
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Kowa

Mechanism of Action

Molecular Targets

celecoxib + tramadol HCl acts on 4 molecular targets:

OPRM1opioid receptor mu 1 (MOP, M-OR-1)
PTGS2prostaglandin-endoperoxide synthase 2 (PHS-2, PGG/HS)
SLC6A2solute carrier family 6 member 2 (NAT1, NET)
SLC6A4solute carrier family 6 member 4 (SERT1, 5-HTTLPR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

celecoxib + tramadol HCl is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Gastrointestinal disordersAbdominal pain✓ Approved
Injury, poisoning and procedural complicationsProcedural painPhase III

Related Research Articles

PubMedAnti-cancer drugs2026-08-30

Prophylactic tramadol for oxaliplatin-induced peripheral vascular pain: a single-arm retrospective study.

Kawaguchi Fumitaka F, Tsuneki Takafumi T, Kobayashi Michiko M, Sano Motohiko M

Oxaliplatin-induced peripheral vascular pain (OIVP) often requires central venous port placement. Conventional preventive strategies have limited efficacy, and the use of some effective analgesics is restricted. This single-center retrospective study evaluated the efficacy and safety of prophylactic tramadol. Electronic medical records of patients who received oxaliplatin-based chemotherapy via a peripheral intravenous line and experienced vascular pain [numerical rating scale (NRS) score ≥ 4] were reviewed. Patients who received prophylactic tramadol in a subsequent cycle were included (n = 23). The primary endpoint was the response rate (≥30% reduction in the NRS score from baseline). The secondary endpoint was the change in NRS score compared with the baseline score in the previous cycle. The response rate was 73.9% [95% confidence interval (CI): 51.6-89.8%]. The median NRS score for OIVP decreased significantly from 7.0 at baseline to 3.0 following tramadol administration (P < 0.0001). Administration greater than or equal to 60 min before infusion was associated with a higher response rate (88.9%; 95% CI: 51.8-99.7%) than administration at 30 min (64.3%; 95% CI: 35.1-87.2%), although this difference was not statistically significant (P = 0.208). Adverse events were mild, with grade 2 nausea reported in two (8.7%; 95% CI: 1.1-28.0%) patients. This exploratory study suggested that prophylactic tramadol was associated with a reduction in pain severity in OIVP, with a favorable safety profile. Thus, tramadol may be a promising and accessible prophylactic option, particularly when access to controlled analgesics is limited.

PMID 42669037
Read full article →
PubMedInternational journal of pharmaceutics: X2026-08-30

Imaging-guided COX-2 inhibition synergizes with photodynamic immunogenic cell death to potentiate checkpoint blockade in colon cancer.

Wu Lina L, Chen Xijun X, He Jiaoling J, Deng Xiaoliang X et al.

Colon cancer is a highly aggressive malignancy lacking specific therapeutic targets. Here, we present a therapeutic strategy that integrates inflammation-driven nanomedicine-based photodynamic therapy (PDT) with immune checkpoint blockade (ICB), with holds the potential to eradicate primary tumors and suppress metastasis. The VC@HSA nanomedicine comprises verteporfin (VER), a photosensitizer that induces immunogenic cell death (ICD), and celecoxib (CXB), an inhibitor of prostaglandin E₂ (PGE₂), co-encapsulated within human serum albumin (HSA). By inhibiting PDT-induced PGE₂ upregulation, CXB enhances ICD while alleviating PGE₂-mediated immunosuppression in the tumor microenvironment. The combination therapy synergizes with anti-PD-L1 treatment to elicit a robust antitumor immune response, characterized by increased infiltration of cytotoxic T lymphocytes. Importantly, the HSA-based nanomedicine enables efficient tumor-targeted delivery and holds potential for imaging-guided therapy due to the intrinsic fluorescence properties of the incorporated components. This coordinated immune activation effectively inhibits the growth of primary and distant colon tumors within a short-term in vivo treatment cycle. Collectively, our findings elucidate the mechanism underlying the co-administration of VER and CXB, demonstrate the advantages of albumin as a superior drug carrier, and establish the combination of VC@HSA with ICB as a promising therapeutic strategy for colon cancer.

PMID 42668486
Read full article →
PubMedJournal of pain research2026-08-29

Efficacy and Safety of Celecoxib Combined with Gabapentin for Head and Facial Pain in Nasopharyngeal Carcinoma: A Retrospective Cohort Study.

Cao Xiangrong X, Xu Linzong L, Ta Weiwei W

Head and facial pain caused by local invasion in nasopharyngeal carcinoma (NPC) is notoriously severe and traditionally managed with opioids, which carry substantial dependence and tolerability risks. Because this tumor-related pain intrinsically involves both neuropathic and inflammatory pathways, we retrospectively evaluated a novel opioid-sparing analgesic strategy combining celecoxib and gabapentin. This exploratory retrospective cohort analysis included 60 newly diagnosed NPC patients experiencing severe head and facial pain secondary to cranial nerve or skull base invasion. Patients received either opioid monotherapy (extended-release oxycodone, n=30) or a combined regimen of celecoxib and gabapentin (n=30). The primary endpoint was the absolute reduction in Numeric Rating Scale (NRS) scores at 48 hours. Secondary endpoints included sleep quality improvement, assessed via the Insomnia Severity Index (ISI), and adverse events. Longitudinal data were rigorously analyzed using Generalized Estimating Equations (GEE) to account for repeated measures and adjust for baseline clinical covariates. Baseline clinical characteristics were broadly comparable between the cohorts, with no statistically significant differences in premedication NRS scores (6.5 in both groups) or ISI scores (16.5 vs 19.5, P = 0.118); however, the combined group had a numerically higher baseline ISI score, and all ISI comparisons were therefore based on change-from-baseline scores. The GEE longitudinal analysis revealed a significant treatment-by-time interaction for pain relief. At the 48-hour primary endpoint, the combined regimen demonstrated a significantly greater absolute reduction in NRS scores compared to the opioid group (Estimated Mean Difference [MD], 2.15; 95% CI, 1.45 to 2.85; P < 0.001). Furthermore, the combined therapy yielded a profoundly larger improvement in sleep architecture (ISI reduction MD, 9.85; 95% CI, 7.50 to 12.20; P < 0.001). Safety profiles analyzed via Fisher's exact test confirmed the combined group had a significantly lower incidence of nausea and vomiting (0.0% vs 20.0%, P = 0.024); no significant between-group differences were observed for other adverse events including constipation, dizziness, and somnolence. Combining celecoxib and gabapentin appears to offer an effective, opioid-sparing alternative for managing complex tumor-related pain in NPC, and was associated with greater pain reduction over the 48-hour observation period, accelerated sleep recovery, and significantly better gastrointestinal tolerability compared to conventional opioid therapy in this retrospective cohort. These findings are hypothesis-generating and warrant prospective validation.

PMID 42666573
Read full article →
PubMedCurrent pain and headache reports2026-08-29

Adjunct Medications for Single-Injection Pediatric Regional Blocks: Implications for Peripheral Nerve Blocks.

Jha Sachin Sunny SS

Single-injection peripheral nerve blocks (PNBs) provide excellent perioperative analgesia in children but are limited by finite duration. Pediatric populations were excluded from the major adult adjunct reviews. This narrative review synthesizes the evidence for adjuncts added to local anesthetics for single-injection PNBs and caudal blocks in patients aged 0 to 18 years, including dexamethasone, dexmedetomidine, clonidine, conventional opioids, buprenorphine, magnesium sulfate, midazolam, ketamine, neostigmine, tramadol, nalbuphine, and epinephrine. Across 58 studies, dexmedetomidine (0.5 to 1 mcg/kg) and dexamethasone (0.1 mg/kg perineural) were the best-supported agents, each roughly doubling analgesic duration with acceptable safety. Two network meta-analyses ranked neostigmine highest for caudal duration, but its postoperative nausea and vomiting burden limits use. Clonidine has the longest safety record. Ketamine and midazolam show robust caudal efficacy but unresolved neurotoxicity concerns. Nalbuphine and buprenorphine are promising but under-studied. Tramadol carries pediatric regulatory restrictions, while epinephrine and conventional opioids add little. Dexmedetomidine and dexamethasone are the preferred adjuncts in pediatric regional anesthesia. Adult evidence should not be extrapolated directly given developmental pharmacology and pediatric-specific safety considerations. Prospective trials in true pediatric PNBs and pediatric rebound-pain studies remain the critical evidence gaps.

PMID 42667510
Read full article →
PubMedJournal of visualized experiments : JoVE2026-08-29

Network-guided Evaluation of β-sitosterol in Inflammatory and Profibrotic Mesangial-Cell Models Relevant to Chronic Glomerulonephritis.

He Haipeng H, He Lian L, Chen Fei F, Cen Jie J et al.

Chronic glomerulonephritis (CGN) is characterized by persistent inflammatory injury and progressive fibrotic remodeling, yet compound-target relationships underlying natural-product-based interventions remain incompletely defined. This study integrated network pharmacology, validated molecular docking, and in vitro experiments to evaluate candidate constituents of Cordyceps sinensis (C. sinensis) in CGN-related pathological processes. Candidate constituents of C. sinensis were screened, and the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform-derived compound-associated targets were intersected with CGN-associated genes. Functional enrichment and protein-protein interaction analyses were used to prioritize biological processes and hub targets. PTGS2 was identified as a key overlapping target. Molecular docking was performed using a celecoxib-bound COX-2 structure. Re-docking of the co-crystallized celecoxib ligand reproduced the crystallographic pose with an RMSD of 0.876 Å, supporting the docking protocol. β-Sitosterol and linoleyl acetate showed predicted compatibility with the COX-2 docking region, with binding affinities of -7.2 and -7.5 kcal/mol, respectively. β-Sitosterol was selected for compound-level validation in HBZY-1 rat glomerular mesangial cells. At 0.5-10 µM, β-sitosterol did not markedly reduce cell viability. In Lipopolysaccharide (LPS)-stimulated cells, β-sitosterol reduced Tnf, Il6, and Ptgs2 expression, decreased prostaglandin E2 (PGE2) production, and reduced cyclooxygenase-2 (COX-2) protein abundance. In transforming growth factor β1 (TGF-β1)-treated cells, β-sitosterol reduced Col1a1 and Acta2 expression and decreased alpha-smooth muscle actin (α-SMA) protein abundance. These findings provide hypothesis-generating evidence that β-sitosterol modulates inflammatory and profibrotic activation in mesangial-cell models, but they do not establish direct COX-2 enzymatic inhibition or therapeutic efficacy in CGN.

PMID 42667189
Read full article →
PubMedFrontiers in oncology2026-08-29

Preemptive analgesia with parecoxib sodium alleviates short-term pain after endoscopic submucosal dissection for early esophageal cancer and precancerous lesions: a single-center, double-arm, and randomized controlled study.

Liu Xiao-Bo XB, Shen Hai-Tao HT, Chen Zi-Mei ZM, Xu Wen W et al.

Endoscopic submucosal dissection (ESD) is the preferred treatment for early esophageal cancer and precancerous lesions. Postoperative pain is a prevalent but often overlooked issue.This study investigated the analgesic efficacy and safety of preemptive parecoxib sodium in patients undergoing ESD for early esophageal cancer and precancerous lesions. Patients scheduled for ESD under general anesthesia were enrolled and randomly allocated to the medication group (intravenous parecoxib sodium 30 minutes prior to surgery) or the control group (4 mL intravenous normal saline 30 minutes before the procedure). Clinical data, including perioperative serum levels of high-sensitivity C-reactive protein, IL-6, complete blood count, and biochemical parameters, were collected. Postoperative pain intensity was assessed using the visual analog scale (VAS) at 6, 12, 24, 72, and 120 hours after the procedure. A total of 78 patients participated (40 in the parecoxib group, 38 in the control group). The two groups were comparable in baseline characteristics and preoperative inflammatory/nutritional indicators (all P > 0.05). At 6 and 12 hours post-operation, pain scores in the medication group were significantly lower than those in the control group (P < 0.05), while VAS scores at 24, 72, and 120 hours showed no significant differences between groups (P > 0.05). The frequency and total dosage of postoperative tramadol administration, as well as the incidence of adverse reactions, were comparable between the two groups (all P > 0.05). Preemptive analgesia with parecoxib sodium can alleviate early postoperative pain in patients with early esophageal cancer and precancerous lesions who undergo ESD for mucosal defects involving less than three-quarters of the esophageal circumference, without increasing adverse reactions or the subsequent use of analgesic drugs. https://www.chictr.org.cn/showproj.html?proj=218572, identifier ChiCTR2400080433.

PMID 42666456
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about celecoxib + tramadol HCl